Panelists at NewYorkBIO-CONference Highlight Prior Clinical Data Showing Iomab™-B Improves Survival and is Well-Tolerated Jun 11, 2014
Actinium KOL Joseph Jurcic, MD to Discuss the Role of Actinium’s Alpha-Particle Radiopharmaceuticals in the Treatment of Leukemia Patients at the 2014 Society of Nuclear Medicine and Molecular Imaging Annual Meeting Jun 5, 2014
Actinium Expands into Additional Offices in Metro Park in Edison, NJ to Support Growing Operations Jun 2, 2014
Actinium’s Clinical Advisory Board Chairman Joseph Jurcic, MD to Present at the 2014 ASCO Annual Meeting May 20, 2014
Leading Experts in the Field of AML Treatment and Bone Marrow Transplant to Discuss Available Treatment Options and Potential New Opportunities Including Actinium’s Iomab™-B at NY BIO CONference May 13, 2014
Actinium Announces Start of Collaboration to Manufacture IomabTM-B for Phase 3 Clinical Trial and Commercialization May 6, 2014